Citations (40)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Olaf Burkhardt & Tobias Welte. (2009) 10 years’ experience with the pneumococcal quinolone moxifloxacin. Expert Review of Anti-infective Therapy 7:6, pages 645-668.
Read now
Read now
Juan-Pablo Caeiro & Paul B Iannini. (2003) Moxifloxacin (Avelox®): a novel fluoroquinolone with a broad spectrum of activity. Expert Review of Anti-infective Therapy 1:3, pages 363-370.
Read now
Read now
Articles from other publishers (38)
Heon Jae Jeong. (2017) A Strategy to Overcome Under-Reporting Issues of Voluntary Medication Error Reporting System, Part II: Changes in Number of Reports by a Counter-error Measure—Computerized Prescriber Order Entry. Biometrics & Biostatistics International Journal 5:5.
Crossref
Crossref
Mohammad Asif. (2017) An Overview on Fluoroquinolone Drugs for the Treatment of Tubercular Infection. International Journal of Biosensors & Bioelectronics 2:1.
Crossref
Crossref
Bo Hyoung KangKyung-Wook JoTae Sun Shim. (2017) Current Status of Fluoroquinolone Use for Treatment of Tuberculosis in a Tertiary Care Hospital in Korea. Tuberculosis and Respiratory Diseases 80:2, pages 143.
Crossref
Crossref
S. Thee, A.J. Garcia-Prats, P.R. Donald, A.C. Hesseling & H.S. Schaaf. (2015) Fluoroquinolones for the treatment of tuberculosis in children. Tuberculosis 95:3, pages 229-245.
Crossref
Crossref
Elisa Chilet-RosellMa Teresa Ruiz-CanteroMa Angeles Pardo. (2014) Gender Analysis of Moxifloxacin Clinical Trials. Journal of Women's Health 23:1, pages 77-104.
Crossref
Crossref
Lilia E Ziganshina, Albina F Titarenko & Geraint R Davies. (2013) Fluoroquinolones for treating tuberculosis (presumed drug-sensitive). Cochrane Database of Systematic Reviews.
Crossref
Crossref
Ying Zhang. 2012. Antibiotic Discovery and Development. Antibiotic Discovery and Development
719
749
.
Marcus B. Conde & José R. Lapa e Silva. (2011) New regimens for reducing the duration of treatment of drug-susceptible pulmonary tuberculosis. Drug Development Research 72:6, pages 501-508.
Crossref
Crossref
Arianna D Pranger, Jos GW Kosterink, Richard van Altena, Rob E Aarnoutse, Tjip S van der Werf, Donald RA Uges & Jan-Willem C Alffenaar. (2011) Limited-Sampling Strategies for Therapeutic Drug Monitoring of Moxifloxacin in Patients With Tuberculosis. Therapeutic Drug Monitoring 33:3, pages 350-354.
Crossref
Crossref
S. Berdot, E. Papy, C. Rioux, S. Diamantis, R. Ruimy, M.-C. Dombret, P. Arnaud & E. Bouvet. (2010) Bilan de l’utilisation de la moxifloxacine dans le traitement de la tuberculose dans un hôpital universitaire. Médecine et Maladies Infectieuses 40:10, pages 568-573.
Crossref
Crossref
Philippe Ichai, Faouzi Saliba, Fadi Antoun, Daniel Azoulay, Mylène Sebagh, Teresa Maria Antonini, Lélia Escaut, Delvart Valérie, Denis Castaing & Didier Samuel. (2010) Acute liver failure due to antitubercular therapy: Strategy for antitubercular treatment before and after liver transplantation. Liver Transplantation 16:10, pages 1136-1146.
Crossref
Crossref
Umesh G. Lalloo & Anish Ambaram. (2010) New Antituberculous Drugs in Development. Current HIV/AIDS Reports 7:3, pages 143-151.
Crossref
Crossref
C. Andrejak. (2010) Traitement des infections pulmonaires à Mycobacterium xenopi. Antibiotiques 12:2, pages 107-113.
Crossref
Crossref
Jossy van den Boogaard, Gibson S. Kibiki, Elton R. Kisanga, Martin J. Boeree & Rob E. Aarnoutse. (2009) New Drugs against Tuberculosis: Problems, Progress, and Evaluation of Agents in Clinical Development. Antimicrobial Agents and Chemotherapy 53:3, pages 849-862.
Crossref
Crossref
Ying Zhang. 2009. Pharmacology and Therapeutics. Pharmacology and Therapeutics
1089
1108
.
S. Bonora, A. Mondo, L. Trentini, A. Calcagno, A. Lucchini & G. Di Perri. (2008) Moxifloxacin for the treatment of HIV-associated tuberculosis in patients with contraindications or intolerance to rifamycins. Journal of Infection 57:1, pages 78-81.
Crossref
Crossref
J. W. C. Alffenaar, P. M. de Vries, G. J. Luijckx, D. van Soolingen, T. S. van der Werf & R. van Altena. (2008) Plasma and Cerebrospinal Fluid Pharmacokinetics of Moxifloxacin in a Patient with Tuberculous Meningitis. Antimicrobial Agents and Chemotherapy 52:6, pages 2293-2295.
Crossref
Crossref
Qijiang Cheng, William Bishai & Eric Nuermberger. 2008. Clinical Tuberculosis 4th Edition. Clinical Tuberculosis 4th Edition
243
252
.
Wing Yew. 2008. Clinical Tuberculosis 4th Edition. Clinical Tuberculosis 4th Edition
225
242
.
Lilia E Ziganshina & Stephen B Squire. 1996. Cochrane Database of Systematic Reviews. Cochrane Database of Systematic Reviews.
Wing Wai YEW & Chi Chiu LEUNG. (2007) Management of multidrug-resistant tuberculosis: Update 2007. Respirology 0:0, pages 071031182005003-???.
Crossref
Crossref
F.-X. Blanc. (2006) Tuberculose : encore plus fort que la multirésistance. Revue des Maladies Respiratoires 23:5, pages 86-88.
Crossref
Crossref
Luigi Ruffo Codecasa, Giovanni Ferrara, Maurizio Ferrarese, Maria Antonietta Morandi, Valeria Penati, Carla Lacchini, Patrizia Vaccarino & Giovanni Battista Migliori. (2006) Long-term moxifloxacin in complicated tuberculosis patients with adverse reactions or resistance to first line drugs. Respiratory Medicine 100:9, pages 1566-1572.
Crossref
Crossref
Arthur M. DannenbergJr.Jr.. 2006. Pathogenesis of Human Pulmonary Tuberculosis. Pathogenesis of Human Pulmonary Tuberculosis
373
384
.
William J. BurmanStefan GoldbergJohn L. JohnsonGrace MuzanyeMelissa EngleAnn W. MosherShurjeel ChoudhriCharles L. DaleySonal S. MunsiffZhen ZhaoAndrew VernonRichard E. Chaisson. (2006) Moxifloxacin versus Ethambutol in the First 2 Months of Treatment for Pulmonary Tuberculosis. American Journal of Respiratory and Critical Care Medicine 174:3, pages 331-338.
Crossref
Crossref
Umesh G Lalloo, Rishendran Naidoo & Anish Ambaram. (2006) Recent advances in the medical and surgical treatment of multi-drug resistant tuberculosis. Current Opinion in Pulmonary Medicine 12:3, pages 179-185.
Crossref
Crossref
Kai Man KamChi Wai YipTze Leung CheungHei Sing TangOi Chi LeungMei Yuk Chan. (2006)
Stepwise Decrease in Moxifloxacin Susceptibility amongst Clinical Isolates of Multidrug-Resistant
Mycobacterium tuberculosis:
Correlation with Ofloxacin Susceptibility
. Microbial Drug Resistance 12:1, pages 7-11.
Crossref
Crossref
Ying Zhang, Katrin Post-Martens & Steven Denkin. (2006) New drug candidates and therapeutic targets for tuberculosis therapy. Drug Discovery Today 11:1-2, pages 21-27.
Crossref
Crossref
Stephen H. Gillespie, Roly D. Gosling, Leonard Uiso, Noel E. Sam, Esther G. Kanduma & Timothy D. McHugh. (2005) Early bactericidal activity of a moxifloxacin and isoniazid combination in smear-positive pulmonary tuberculosis. Journal of Antimicrobial Chemotherapy 56:6, pages 1169-1171.
Crossref
Crossref
Ying Zhang. (2005) THE MAGIC BULLETS AND TUBERCULOSIS DRUG TARGETS. Annual Review of Pharmacology and Toxicology 45:1, pages 529-564.
Crossref
Crossref
Regis P. Kowalski, Eric G. Romanowski, Francis S. Mah, Kathleen A. Yates & Y. Jerold Gordon. (2005) Intracameral Vigamox® (Moxifloxacin 0.5%) is Non-Toxic and Effective in Preventing Endophthalmitis in a Rabbit Model. American Journal of Ophthalmology 140:3, pages 497.e1-497.e11.
Crossref
Crossref
LE Ziganshina, AA Vizel & SB Squire. 1996. Cochrane Database of Systematic Reviews. Cochrane Database of Systematic Reviews.
Richard J. O'Brien & Mel Spigelman. (2005) New Drugs for Tuberculosis: Current Status and Future Prospects. Clinics in Chest Medicine 26:2, pages 327-340.
Crossref
Crossref
F. Van Bambeke, J.-M. Michot, J. Van Eldere & P.M. Tulkens. (2005) Quinolones in 2005: an update. Clinical Microbiology and Infection 11:4, pages 256-280.
Crossref
Crossref
Glenn J. Fennelly. (2004) Therapy for Mycobacterium bovis. The Pediatric Infectious Disease Journal 23:11, pages 1072-1073.
Crossref
Crossref
Eric L. Nuermberger, Tetsuyuki Yoshimatsu, Sandeep Tyagi, Richard J. O'Brien, Andrew N. Vernon, Richard E. Chaisson, William R. Bishai & Jacques H. Grosset. (2004) Moxifloxacin-containing Regimen Greatly Reduces Time to Culture Conversion in Murine Tuberculosis. American Journal of Respiratory and Critical Care Medicine 169:3, pages 421-426.
Crossref
Crossref
Thomas R Frieden, Timothy R Sterling, Sonal S Munsiff, Catherine J Watt & Christopher Dye. (2003) Tuberculosis. The Lancet 362:9387, pages 887-899.
Crossref
Crossref
Amy Sarah Ginsburg, Jacques H Grosset & William R Bishai. (2003) Fluoroquinolones, tuberculosis, and resistance. The Lancet Infectious Diseases 3:7, pages 432-442.
Crossref
Crossref